ICICI Securities Limited
Solara Active Pharma’s (Solara) Q1FY23 performance was below our estimates across all parameters. Revenue declined 18.6% YoY (-8.5%QoQ) to Rs.3.3bn (I-Sec: Rs.3.8bn) with slower recovery across segments.
Number of FII/FPI investors increased from 66 to 74 in Jun 2026 qtr.
More from Solara Active Pharma Sciences Ltd.
Recommended